An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis
Julien Paccou, René-Marc Flipo Department of Rheumatology, Lille University Hospital, Lille, France Abstract: Golimumab (Simponi®) is a fully human tumor necrosis factor α inhibitor (TNFi) antibody administered subcutaneously. In the European Union, golimumab is indica...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-07-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/an-appraisal-of-golimumab-in-the-treatment-of-severe-active-nonradiogr-peer-reviewed-article-DDDT |